Step-by-step Development of a Cold Ischemia Device for Open and Robotic-assisted Renal Transplantation.


Journal

European urology
ISSN: 1873-7560
Titre abrégé: Eur Urol
Pays: Switzerland
ID NLM: 7512719

Informations de publication

Date de publication:
Dec 2021
Historique:
received: 09 03 2021
accepted: 20 05 2021
pubmed: 2 6 2021
medline: 19 4 2022
entrez: 1 6 2021
Statut: ppublish

Résumé

Kidney transplantation (KT) is the best renal replacement treatment. The rewarming time is associated with ischemia/reperfusion damage. In both the open (open KT [OKT]) and the robotic (robotic-assisted KT [RAKT]) approaches, ice slush is used to maintain graft temperature (T°) below 20 °C. This may result in nonhomogeneous graft T° maintenance and, particularly during RAKT where the graft is completely inside the abdominal cavity, rises concerns regarding systemic hypothermia. To design a cold ischemia device (CID) to maintain a constant and homogeneous low graft T° during surgery. In IDEAL phase 0, a CID was developed and tested to determine its cooling effect on the kidney inside a closed system at 37.5 °C, by comparing it with kidney alone versus a gauze-jacket filled with ice slush. The CID was evaluated in pigs undergoing OKT and RAKT, assessing feasibility and adverse reactions. In IDEAL phase 1, the CID was tested in human OKT and RAKT. OKT and RAKT. In all phases, T° was evaluated at scheduled time points. In the preliminary tests of IDEAL phase 0, the CID was able to maintain a low graft T° and superiority to other groups (p =  0.002). In the in vivo animal model, the CID maintained a low and constant graft T° in OKT (n = 3) and RAKT (n = 3), with a mean T° at 50 min of 10.8 °C and 14.9 °C, respectively. IDEAL phase 1 demonstrated feasibility of both approaches (OKT, n = 2 and RAKT, n = 3) using the CID, and graft T° never exceeded 20 °C (mean T°: OKT 15.7 °C vs RAKT 18.3 °C). No complications were recorded. The main limitation consists in the low number of participants. The CID assured a constant low graft T° during rewarming time, in both OKT and RAKT. A cold ischemia device (CID) is the first step toward a feasible, safe, and reproducible method to maintain a low graft temperature during surgery. The employment of a CID may optimize the functional outcomes.

Sections du résumé

BACKGROUND BACKGROUND
Kidney transplantation (KT) is the best renal replacement treatment. The rewarming time is associated with ischemia/reperfusion damage. In both the open (open KT [OKT]) and the robotic (robotic-assisted KT [RAKT]) approaches, ice slush is used to maintain graft temperature (T°) below 20 °C. This may result in nonhomogeneous graft T° maintenance and, particularly during RAKT where the graft is completely inside the abdominal cavity, rises concerns regarding systemic hypothermia.
OBJECTIVE OBJECTIVE
To design a cold ischemia device (CID) to maintain a constant and homogeneous low graft T° during surgery.
DESIGN, SETTING, AND PARTICIPANTS METHODS
In IDEAL phase 0, a CID was developed and tested to determine its cooling effect on the kidney inside a closed system at 37.5 °C, by comparing it with kidney alone versus a gauze-jacket filled with ice slush. The CID was evaluated in pigs undergoing OKT and RAKT, assessing feasibility and adverse reactions. In IDEAL phase 1, the CID was tested in human OKT and RAKT.
SURGICAL PROCEDURE METHODS
OKT and RAKT.
MEASUREMENTS METHODS
In all phases, T° was evaluated at scheduled time points.
RESULTS AND LIMITATIONS CONCLUSIONS
In the preliminary tests of IDEAL phase 0, the CID was able to maintain a low graft T° and superiority to other groups (p =  0.002). In the in vivo animal model, the CID maintained a low and constant graft T° in OKT (n = 3) and RAKT (n = 3), with a mean T° at 50 min of 10.8 °C and 14.9 °C, respectively. IDEAL phase 1 demonstrated feasibility of both approaches (OKT, n = 2 and RAKT, n = 3) using the CID, and graft T° never exceeded 20 °C (mean T°: OKT 15.7 °C vs RAKT 18.3 °C). No complications were recorded. The main limitation consists in the low number of participants.
CONCLUSIONS CONCLUSIONS
The CID assured a constant low graft T° during rewarming time, in both OKT and RAKT.
PATIENT SUMMARY RESULTS
A cold ischemia device (CID) is the first step toward a feasible, safe, and reproducible method to maintain a low graft temperature during surgery. The employment of a CID may optimize the functional outcomes.

Identifiants

pubmed: 34059396
pii: S0302-2838(21)01795-4
doi: 10.1016/j.eururo.2021.05.026
pii:
doi:

Substances chimiques

Ice 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

738-745

Informations de copyright

Copyright © 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Auteurs

Angelo Territo (A)

Department of Urology, Fundació Puigvert, Autonoma University of Barcelona, Spain.

Alberto Piana (A)

Department of Urology, Fundació Puigvert, Autonoma University of Barcelona, Spain. Electronic address: alb.piana@gmail.com.

Matteo Fontana (M)

Department of Urology, Fundació Puigvert, Autonoma University of Barcelona, Spain.

Pietro Diana (P)

Department of Urology, Fundació Puigvert, Autonoma University of Barcelona, Spain.

Andrea Gallioli (A)

Department of Urology, Fundació Puigvert, Autonoma University of Barcelona, Spain.

Josep Maria Gaya (JM)

Department of Urology, Fundació Puigvert, Autonoma University of Barcelona, Spain.

Jordi Huguet (J)

Department of Urology, Fundació Puigvert, Autonoma University of Barcelona, Spain.

Pavel Gavrilov (P)

Department of Urology, Fundació Puigvert, Autonoma University of Barcelona, Spain.

Óscar Rodríguez-Faba (Ó)

Department of Urology, Fundació Puigvert, Autonoma University of Barcelona, Spain.

Carmen Facundo (C)

Department of Nephrology, Fundació Puigvert, Autonoma University of Barcelona, Spain.

Lluis Guirado (L)

Department of Nephrology, Fundació Puigvert, Autonoma University of Barcelona, Spain.

Joan Palou (J)

Department of Urology, Fundació Puigvert, Autonoma University of Barcelona, Spain.

Alex Mottrie (A)

ORSI Academy, Melle, Belgium.

Alberto Breda (A)

Department of Urology, Fundació Puigvert, Autonoma University of Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH